Do analysts recommend EDIT or BNR?

Editas Medicine presently has a consensus target price of $6.00, suggesting a potential upside of 122.22%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer EDIT or BNR?

In the previous week, Editas Medicine had 7 more articles in the media than Burning Rock Biotech. MarketBeat recorded 12 mentions for Editas Medicine and 5 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.63 beat Editas Medicine's score of 0.62 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PBYI or BNR?

Puma Biotechnology currently has a consensus target price of $6.00, suggesting a potential downside of 34.21%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PBYI or BNR?

In the previous week, Puma Biotechnology and Puma Biotechnology both had 5 articles in the media. Puma Biotechnology's average media sentiment score of 0.76 beat Burning Rock Biotech's score of 0.63 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate KMDA or BNR?

Kamada currently has a consensus target price of $13.00, suggesting a potential upside of 64.14%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to KMDA or BNR?

In the previous week, Burning Rock Biotech had 3 more articles in the media than Kamada. MarketBeat recorded 5 mentions for Burning Rock Biotech and 2 mentions for Kamada. Kamada's average media sentiment score of 0.93 beat Burning Rock Biotech's score of 0.63 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BNR or CCCC?

C4 Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 118.42%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 C4 Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Do analysts recommend BNR or ELYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Burning Rock Biotech (BNR) Competitors

$12.28 +0.66 (+5.68%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.17 -0.11 (-0.90%)

As of 09/11/2026 07:30 PM Eastern

Compare

BNR vs. EDIT, PBYI, KMDA, CCCC, and ELYM

Should you buy Burning Rock Biotech stock or one of its competitors? Burning Rock Biotech's main competitors and comparable companies include Editas Medicine (EDIT), Puma Biotechnology (PBYI), Kamada (KMDA), C4 Therapeutics (CCCC), and Eliem Therapeutics (ELYM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Burning Rock Biotech compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Editas Medicine has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Burning Rock Biotech has a net margin of -13.60% compared to Editas Medicine's net margin of -157.32%. Burning Rock Biotech's return on equity of -12.86% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Burning Rock Biotech	-13.60%	-12.86%	-8.51%

Burning Rock Biotech has higher revenue and earnings than Editas Medicine. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A
Burning Rock Biotech	$514.43M	0.25	-$7.92M	-$0.87	N/A

Editas Medicine presently has a consensus target price of $6.00, suggesting a potential upside of 122.22%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Editas Medicine had 7 more articles in the media than Burning Rock Biotech. MarketBeat recorded 12 mentions for Editas Medicine and 5 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.63 beat Editas Medicine's score of 0.62 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Editas Medicine beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Puma Biotechnology has higher earnings, but lower revenue than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.06	$31.11M	$0.52	17.54
Burning Rock Biotech	$514.43M	0.25	-$7.92M	-$0.87	N/A

Puma Biotechnology currently has a consensus target price of $6.00, suggesting a potential downside of 34.21%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Puma Biotechnology has a net margin of 11.50% compared to Burning Rock Biotech's net margin of -13.60%. Puma Biotechnology's return on equity of 20.76% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Burning Rock Biotech	-13.60%	-12.86%	-8.51%

In the previous week, Puma Biotechnology and Puma Biotechnology both had 5 articles in the media. Puma Biotechnology's average media sentiment score of 0.76 beat Burning Rock Biotech's score of 0.63 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Puma Biotechnology beats Burning Rock Biotech on 11 of the 14 factors compared between the two stocks.

How does Burning Rock Biotech compare to Kamada?

Kamada (NASDAQ:KMDA) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

20.4% of Kamada shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kamada has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

In the previous week, Burning Rock Biotech had 3 more articles in the media than Kamada. MarketBeat recorded 5 mentions for Burning Rock Biotech and 2 mentions for Kamada. Kamada's average media sentiment score of 0.93 beat Burning Rock Biotech's score of 0.63 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada has a net margin of 11.60% compared to Burning Rock Biotech's net margin of -13.60%. Kamada's return on equity of 8.37% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Burning Rock Biotech	-13.60%	-12.86%	-8.51%

Kamada has higher earnings, but lower revenue than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.52	$20.20M	$0.38	20.84
Burning Rock Biotech	$514.43M	0.25	-$7.92M	-$0.87	N/A

Kamada currently has a consensus target price of $13.00, suggesting a potential upside of 64.14%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Kamada beats Burning Rock Biotech on 12 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to C4 Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

C4 Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 118.42%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Burning Rock Biotech had 4 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Burning Rock Biotech and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.51 beat Burning Rock Biotech's score of 0.63 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Burning Rock Biotech	Positive
C4 Therapeutics	Very Positive

Burning Rock Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, suggesting that its share price is 194% more volatile than the broader market.

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Burning Rock Biotech has a net margin of -13.60% compared to C4 Therapeutics' net margin of -289.44%. Burning Rock Biotech's return on equity of -12.86% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.86%	-8.51%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Burning Rock Biotech has higher revenue and earnings than C4 Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.25	-$7.92M	-$0.87	N/A
C4 Therapeutics	$35.04M	12.32	-$104.99M	-$1.00	N/A

Summary

Burning Rock Biotech and C4 Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Eliem Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Eliem Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.86% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.86%	-8.51%
Eliem Therapeutics	N/A	-47.03%	-45.97%

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Burning Rock Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.25	-$7.92M	-$0.87	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Burning Rock Biotech had 5 more articles in the media than Eliem Therapeutics. MarketBeat recorded 5 mentions for Burning Rock Biotech and 0 mentions for Eliem Therapeutics. Burning Rock Biotech's average media sentiment score of 0.63 beat Eliem Therapeutics' score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Positive
Eliem Therapeutics	Neutral

Summary

Burning Rock Biotech beats Eliem Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$122.22M	$3.84B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-14.11	14.25	275.24	25.29
Price / Sales	0.25	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	1.69	15.12	10.33	6.20
Net Income	-$7.92M	-$22.86M	$3.50B	$358.50M
7 Day Performance	2.42%	-4.34%	-3.32%	-2.35%
1 Month Performance	23.67%	-0.02%	-0.41%	-2.77%
1 Year Performance	44.62%	40.64%	19.21%	7.63%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	0.9461 of 5 stars	$12.28 +5.7%	N/A	+38.9%	$122.22M	$514.43M	N/A	1,390	News Coverage Analyst Upgrade
EDIT Editas Medicine	2.2607 of 5 stars	$3.03 -6.2%	$6.00 +98.0%	-0.4%	$496.06M	$40.52M	N/A	230	News Coverage Gap Down
PBYI Puma Biotechnology	1.0633 of 5 stars	$9.39 -1.7%	$6.00 -36.1%	+102.7%	$492.97M	$228.40M	18.06	200	Gap Down
KMDA Kamada	4.9335 of 5 stars	$8.29 -2.9%	$13.00 +56.8%	+13.0%	$491.09M	$180.46M	21.82	360	Gap Down High Trading Volume
CCCC C4 Therapeutics	1.581 of 5 stars	$3.55 -5.6%	$7.67 +116.0%	+28.6%	$462.57M	$35.04M	N/A	150	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. EDIT, PBYI, KMDA, CCCC, and ELYM

How does Burning Rock Biotech compare to Editas Medicine?

Summary

How does Burning Rock Biotech compare to Puma Biotechnology?

Summary

How does Burning Rock Biotech compare to Kamada?

Summary

How does Burning Rock Biotech compare to C4 Therapeutics?

Summary

How does Burning Rock Biotech compare to Eliem Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. EDIT, PBYI, KMDA, CCCC, and ELYM

How does Burning Rock Biotech compare to Editas Medicine?

Which has more risk & volatility, EDIT or BNR?

Is EDIT or BNR more profitable?

Which has stronger earnings and valuation, EDIT or BNR?

Do analysts recommend EDIT or BNR?

Do insiders and institutionals hold more shares of EDIT or BNR?

Does the media prefer EDIT or BNR?

Summary

How does Burning Rock Biotech compare to Puma Biotechnology?

Do insiders and institutionals hold more shares of PBYI or BNR?

Which has more risk and volatility, PBYI or BNR?

Which has preferable valuation & earnings, PBYI or BNR?

Do analysts rate PBYI or BNR?

Is PBYI or BNR more profitable?

Does the media prefer PBYI or BNR?

Summary

How does Burning Rock Biotech compare to Kamada?

Do insiders & institutionals have more ownership in KMDA or BNR?

Which has more volatility & risk, KMDA or BNR?

Does the media refer more to KMDA or BNR?

Is KMDA or BNR more profitable?

Which has preferable earnings & valuation, KMDA or BNR?

Do analysts rate KMDA or BNR?

Summary

How does Burning Rock Biotech compare to C4 Therapeutics?

Do analysts rate BNR or CCCC?

Does the media prefer BNR or CCCC?

Which has more volatility and risk, BNR or CCCC?

Do institutionals & insiders hold more shares of BNR or CCCC?

Is BNR or CCCC more profitable?

Which has better valuation & earnings, BNR or CCCC?

Summary

How does Burning Rock Biotech compare to Eliem Therapeutics?

Is BNR or ELYM more profitable?

Do insiders & institutionals have more ownership in BNR or ELYM?

Do analysts recommend BNR or ELYM?

Which has more risk & volatility, BNR or ELYM?

Which has better valuation and earnings, BNR or ELYM?

Does the media favor BNR or ELYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools